Loading
Encompass Health Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CARMICHAEL GREG D, was filed 07 May 2024.
Encompass Health Corp: what insiders have been doing
This page follows insider dealings at Encompass Health Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Birmingham, United States. The group dates from 1984. From 20 October 2025 to 20 October 2026, the disclosure feed for Encompass Health Corp logged 84 filings by 19 insiders.
The flow runs one way only: 9 sales worth €25.7M, from 6 insiders, and no purchase. Biggest ticket of the year: €18.6M, sold by Tarr Mark J and made public on 11 August 2026 (0.18% of market cap).
For context, the typical company on the same exchange (median of 5,453 companies) published 22 filings over the same period, against 84 filings here. The full history, which starts in 2016, counts 16 purchases against 26 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 5.94 bn USD and net income at 566.2 m USD, and the dividend at 0.72 USD per share.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
741
Thresholds
n/a
Buy Volume
€9M
16 ops. · all time
Sell Volume
€41M
26 ops. · all time
Who traded when
BuySaleDouglas E. Coltharp4 sales
John Patrick Darby3 sales
Mark J. Tarr3 sales
Andrew L. Price2 sales
Tuer Patrick William2 sales
Charbonneau Elissa Joy1 sale
+1 other insider
Since the insiders bought
- +35.9%Entry US$85.29 · Close at T+365 US$115.91
- +23.4%Entry US$46.69 · Close at T+365 US$57.62
- +26.3%Entry US$26.13 · Close at T+365 US$33.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Encompass Health Corp Strong Buy (bullish), based on 12 analysts. Average price target: US$148.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 5,096 of 26,279 companies
67.4
score / 100
Value58
Quality77
FCF yld3.6%
Earn yld4.7%
EV/EBITDA10.5x
ROE25%
Gross mgn96%
Net mgn9.5%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$122.56
Analyst consensus
12 analystsStrong buy
US$140.00Target US$148.17(+21%)US$155.00
Income statement
RevenueUS$5.9B
Gross profitUS$5.7B96% margin
EBITDAUS$1.4B24% margin
Net incomeUS$564.7M10.0% margin
Valuation
PER (trailing)20.5x
PER (forward)18.4x
P/Book4.7x
Beta0.60
Balance sheet & cash
Market capUS$12.1B
Total debtUS$2.7B
Free Cash FlowUS$439.2M
Debt / Equity82%
Profitability & ownership
ROE25.0%
ROA9.8%
% insiders0.9%
% institutions100.8%
Last declaration on 19 October 2026
Declarations741 total
28 shares0Encompass Health Common StockSEC:0000785161-26-000232:0
38 shares0Encompass Health Common StockSEC:0000785161-26-000226:0
20 shares0Encompass Health Common StockSEC:0000785161-26-000223:0
28 shares0Encompass Health Common StockSEC:0000785161-26-000231:0
81 shares0Encompass Health Common StockSEC:0000785161-26-000225:0
11 shares0Encompass Health Common StockSEC:0000785161-26-000224:0
221 shares@ US$126.630.0002% mcap25.7% of flowEncompass Health Common StockSEC:0000785161-26-000224:1
284 shares@ US$126.890.0003% mcap18.7% of flowEncompass Health Common StockSEC:0000785161-26-000223:1
4 shares0Encompass Health Common StockSEC:0000785161-26-000222:0
18 shares0Encompass Health Common StockSEC:0000785161-26-000221:0
81 shares0Encompass Health Common StockSEC:0000785161-26-000220:0
4,858 shares@ US$35.060.0014% mcap2.4% of flowEncompass Health Common StockSEC:0000785161-26-000208:0
4,858 shares@ US$121.090.0048% mcap8.4% of flowEncompass Health Common StockSEC:0000785161-26-000208:1
5,211 shares@ US$120.930.0051% mcap26.2% of flowEncompass Health Common StockSEC:0000785161-26-000209:0
4,858 shares@ US$121.09010.0048% mcap34.3% of flowCommon StockSEC144:0001969223-26-000967
18,869 shares@ US$125.380.019% mcap13.7% of flowEncompass Health Common StockSEC:0000785161-26-000192:0
171,569 shares@ US$125.460.18% mcap53.1% of flowEncompass Health Common StockSEC:0000785161-26-000191:0
1,579 shares@ US$126.060.0016% mcap0.5% of flowEncompass Health Common StockSEC:0000785161-26-000191:1
8,906 shares@ US$125.950.0092% mcap16.0% of flowEncompass Health Common StockSEC:0000785161-26-000190:0
18,869 shares@ US$125.3750.019% mcap100.0% of flowCommon StockSEC144:0001969223-26-000876
8,906 shares@ US$125.94890.0092% mcap65.7% of flowCommon StockSEC144:0001969223-26-000877
319 shares@ US$112.400.0003% mcap22.4% of flowEncompass Health Common StockSEC:0000785161-26-000180:1
11 shares0Encompass Health Common StockSEC:0000785161-26-000178:0
19 shares0Encompass Health Common StockSEC:0000785161-26-000172:0
25 of 741 declarations
About Encompass Health Corp
Encompass Health Corp. (NYSE: EHC) is a leading U.S. provider of inpatient rehabilitation hospital services in the United States, headquartered in Birmingham, Alabama. The company was founded in 1984 as HealthSouth and completed its rebranding to Encompass Health in 2019. Today, it operates the largest network of inpatient rehabilitation hospitals in the country and is widely positioned as a specialist in intensive post-acute care for patients recovering from stroke, orthopedic surgery, neurological conditions, and other complex medical events.
The company’s core business is centered on operating inpatient rehabilitation hospitals, supported by a meaningful network of joint ventures with acute-care hospitals and health systems. Its clinical model combines three hours of therapy per day, five days per week, frequent physician oversight, 24/7 nursing care, and multidisciplinary rehabilitation services. This integrated service offering is designed to restore function and help patients return home more quickly and safely, which is an important differentiator versus other post-acute care alternatives.
Read moreShow less
From a competitive standpoint, Encompass Health benefits from scale, specialized clinical expertise, and a strong reputation with referral sources, payors, and patients. In its 2024 annual report, management emphasized a substantial unmet need for inpatient rehabilitation services in the U.S., driven by demographic aging and a constrained supply of licensed rehabilitation beds. The company also highlighted its breadth of operations, noting that 65 of its 166 hospitals were operated as joint ventures, which supports market access and local partnerships. These factors underpin its position as a national leader in a niche but strategically important segment of healthcare delivery.
Geographically, Encompass Health has a broad U.S. footprint across numerous states. Its principal corporate offices and home office are in Birmingham, Alabama. The network continues to expand through new hospital openings and bed additions, reinforcing the company’s growth strategy. In 2025, for example, the company announced plans for a new inpatient rehabilitation hospital in North Las Vegas and later opened a new hospital in St. Petersburg, Florida, signaling continued investment in capacity expansion.
Recent developments are also notable. In February 2026, Encompass Health reported strong fourth-quarter and full-year 2025 results, with revenue growth, EBITDA expansion, and additional capacity added during the year. Management also provided 2026 guidance and reiterated the long-term demand tailwind from an aging U.S. population. For investors, Encompass Health offers a defensive healthcare profile, a specialized market niche, and exposure to a structural demographic growth theme, all while remaining listed on the NYSE in the United States.
